Cox regression analysis regarding the impact of CR evaluation on OS and RFS
| . | Non-sCR vs sCR . | |
|---|---|---|
| HR . | 95% CI . | |
| OS | ||
| Crude | 1.41 | 1.17-1.69 |
| Age and sex adjusted | 1.32 | 1.10-1.59 |
| Fully adjusted* | 1.34 | 1.10-1.64 |
| RFS | ||
| Crude | 1.28 | 1.08-1.53 |
| Age and sex adjusted | 1.23 | 1.03-1.47 |
| Fully adjusted* | 1.25 | 1.03-1.51 |
| . | Non-sCR vs sCR . | |
|---|---|---|
| HR . | 95% CI . | |
| OS | ||
| Crude | 1.41 | 1.17-1.69 |
| Age and sex adjusted | 1.32 | 1.10-1.59 |
| Fully adjusted* | 1.34 | 1.10-1.64 |
| RFS | ||
| Crude | 1.28 | 1.08-1.53 |
| Age and sex adjusted | 1.23 | 1.03-1.47 |
| Fully adjusted* | 1.25 | 1.03-1.51 |
Adjusted for age, sex, World Health Organization performance score at diagnosis, leukocyte count at diagnosis, CR as response after first or second induction therapy, and cytogenetic risk group.